Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Mineralys Therapeutics, Inc.NASDAQ: MLYS

Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other current liabilities remains negative

Q2 FY2026 other current liabilities was $0, compared with $2.62M a year earlier. Over 3 fiscal years it compounded at +124.8% a year.

Context

  • Other current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
  • Other current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$7.56M+110.9% YoY
Year agoJun 2025
$2.62M-100.0% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+110.9%——
3-year CAGR+124.8%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
7.56M USD
Year-over-year change
+110.9%
4-year CAGR
+121.7%

Other Current Liabilities vs competitors

How MLYS compares with its peers on the latest reported figures

  • MLYS's Jun 2026 other current liabilities of $0 is the 6th highest of the 7 companies compared; the peer median is $5.43M.
  • Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of +111.1%.
  • Other current liabilities amounts to 0.0% of total assets for MLYS, versus a peer median of 3.4%.
MLYS Competitors Peer median
Other Current Liabilities for MLYS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TVTXTravere Therapeutics, Inc.Sep 2026$204.6M +521.1%-2.3%24.1%
UNCYUnicycive Therapeutics, Inc.Mar 2026$21.7M +104.9%—33.7%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$5.44M +448.2%+29.4%5.4%
MAZEMaze Therapeutics, Inc.Mar 2026$5.42M -25.5%+13.2%1.3%
DMACDiaMedica Therapeutics Inc.Mar 2026$741K +117.3%+27.4%1.4%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 -100.0%+124.8%0.0%
VERAVera Therapeutics, Inc.Jun 2026$0 -100.0%—0.0%
Peer median (excluding MLYS) $5.43M+111.1%+20.3%3.4%

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.61M87.7M49.3M114.09M172.92M
Short-term Investments022.41M187.26M84.1M483.71M
Net Receivables00000
Inventory00000
Other Current Assets50K2.7M12.54M7.16M4.75M
Total Current Assets11.12M112.81M249.1M205.35M661.39M
Property, Plant & Equipment (Net)00053K38K
Goodwill00000
Intangible Assets00000
Long-term Investments002.48M00
Tax Assets00000
Other Non-current Assets3K1.63M51K499K382K
Total Non-current Assets3K1.63M2.53M552K420K
Total Assets11.13M114.44M251.64M205.9M661.81M
Account Payables763K1.91M601K479K2.02M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities313K665K1.6M3.58M7.56M
Total Current Liabilities5.05M8.07M10.48M14.65M15.11M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities29M158.64M000
Total Non-current Liabilities29M158.64M000
Total Liabilities34.05M166.71M10.48M14.65M15.11M
Common Stock1K1K4K5K8K
Retained Earnings(23.01M)(52.81M)(124.71M)(302.52M)(457.17M)
Accumulated OCI00(251.64M)00
Other Stockholders Equity(29M)0000
Minority Interest00000
Total Equity(22.93M)(52.27M)241.15M191.26M646.69M
Total Debt00000
Net Debt(10.61M)(87.7M)(49.3M)(114.09M)(172.92M)

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.